scholarly journals Evaluation of pediatric patients with јuvenile idiopathic arthritis treated with biological therapy Tocilizumab (Actemra)

2021 ◽  
Vol 13 (2) ◽  
Author(s):  
Marija Neskovska-Sumenkovska ◽  
Aspazija Sofijanova ◽  
Rozana Kacarska ◽  
Konstandina Kuzevska-Maneva ◽  
Beti Gjurkova Angelovska ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Biological Therapy ◽  
Severe Form ◽  
Common Chronic Disease ◽  
Purified Protein Derivative ◽  
Pediatric Diseases ◽  
Therapeutic Choice ◽  
Laboratory Investigations ◽  
Significant Therapeutic Effect ◽  
Systemic Form

Juvenile idiopathic arthritis (JIA) is the most common chronic disease in childhood. It manifests a heterogenic group of symptoms of arthritis, lasting at least 6 weeks and it appears before the age of 16. Patients who had no good therapeutic response to conventional therapy with Methotrexate were treated with biological therapy. The aim of this paper was to evaluate 9 patients who were receiving Tocilizumab at the Department of Rheumocardiology, University Clinic of Pediatric Diseases in Skopje. Materials and methods: Our study included 9 patients treated at our Department with biological therapy with Tocilizumab. Prior to initiation of the biological therapy, all patients underwent laboratory investigations, purified protein derivative (PPD) skin test for tuberculosis, X ray of the lungs and heart, and analysis of hepatitis markers. All patients were treated with amp. Actemra (tocilizumab) 8 mg/kg/tt i.v. Two of the patients had a severe form of the disease (one with severe systemic form and one with severe oligoarticular form of JIA). All presented patients had clinical remission of the disease. Conclusion: Therapy with tocilizumab in patients with juvenile idiopathic arthritis is a good therapeutic choice. The results obtained in our study have shown a significant therapeutic effect of tocilizumab even in severe forms of the disease.  

Biological therapy of chronic rhinosinusitis

2021 ◽  
Vol 70 (2) ◽  
pp. 109-114
Author(s):  
Zuzana Balatková ◽  
Zdeněk Knížek ◽  
Jan Vodička ◽  
Jan Plzák
Keyword(s):  
Chronic Rhinosinusitis ◽  
Nasal Polyps ◽  
Biological Therapy ◽  
Immunoglobulin E ◽  
Sinus Surgery ◽  
Therapeutic Choice ◽  
First Choice ◽  
Intranasal Steroids

The aim of this paper is to present an up-to-date information about therapeutical options in chronic rhinosinusitis with nasal polyps. First choice therapy is a long term regular application of intranasal steroids in combination with salinic solution douches. If this treatment is not eff ective enough, then the pulses of systemic steroids are indicated. If the sufficient control of the disease is not achieved, then surgery is a therapeutic choice; it means functional endoscopic sinus surgery in the extent corresponding to the extension of the sinus disease. However, there remains a certain group of patients in whom the results with this treatment are not optimal. The type 2 immunopathological response affects relevantly the course of the disease. Nowadays, the research is done in this field. Specific agents, which are able to block circulating inflammatory mediators or bind receptors for these mediators are developed and studied. The results of the studies having been completed by now are promising. Keywords: biological therapy – chronic rhinosinusitis – nasal polyps – dupilumab – immunoglobulin E – interleukin

scholarly journals Persistence and adherence to biologic therapies in juvenile idiopathic arthritis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Juan Carlos Nieto-González ◽  
Laura Trives-Folguera ◽  
Alejandra Melgarejo-Ortuño ◽  
Aranzazu Ais ◽  
Belén Serrano-Benavente ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Biological Therapy ◽  
Medication Possession Ratio ◽  
Chronic Inflammatory Disease ◽  
First Year ◽  
Medication Persistence ◽  
Biologic Therapies ◽  
Kaplan Meier ◽  
Persistence Rate ◽  
Remission Criteria

AbstractJuvenile idiopathic arthritis (JIA) is a chronic inflammatory disease that often requires biological therapy to control its activity. Medication persistence and adherence are important aspects on which we have scarce information. We performed a longitudinal, retrospective, and observational study based on data from the daily clinical management of JIA patients. We recorded clinical remission at 6 and 12 months. Persistence of biological therapy was evaluated using Kaplan–Meier curves, and adherence was assessed using the medication possession ratio (MPR). We included 68 patients who received biological therapy. Of these, 11 (16.2%) and 5 (7.4%) required a second and third drug, respectively. The persistence rate for biological therapy at 5 years was 64%, with no differences between the first and second lines. Adherence was high during the first year of treatment (MPR80: 96.3%) and also in the second and third years (MPR80: 85.2% and 91.8%, respectively). Persistence and adherence to biological therapy were remarkably high in our JIA cohort. Adherence to biological treatments could be related to a higher probability of fulfilling the Wallace remission criteria at 6 months, although this was not confirmed at 12 months.

FRI0531 Drug Survival of Biological Therapy in Patients with Juvenile Idiopathic Arthritis: 10 Years Experience in a Single Center

2015 ◽  
Vol 74 (Suppl 2) ◽  
pp. 620.3-621
Author(s):  
S.V. Arsenyeva ◽  
I.P. Nikishina ◽  
M.I. Kaleda ◽  
A.N. Shapovalenko ◽  
S.R. Rodionovskaya ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Biological Therapy ◽  
Single Center ◽  
Drug Survival

Analysis of uveitis associated with juvenile idiopathic arthritis using the data from the Moscow city register of children with rheumatic diseases

2020 ◽  
Vol 15 (4) ◽  
pp. 86-90
Author(s):  
V.K. Sevostyanov ◽  
◽  
A.O. Davydov ◽  
A.S. Novikov ◽  
A.I. Polukhina ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Early Diagnosis ◽  
Key Words ◽  
Rheumatic Diseases ◽  
Vision Loss ◽  
Biological Therapy ◽  
Juvenile Arthritis ◽  
Moscow City ◽  
Eye Lesions ◽  
Timely Treatment

Objective. To evaluate the frequency, nature, and structure of therapy for uveitis associated with juvenile idiopathic arthritis (JIA) using the data from the Moscow city register of children with rheumatic diseases. Patients and methods. We analyzed the data of 117 patients with JIA and uveitis aged between 3 and 17 years residing in Moscow. Results. JIA-associated uveitis was diagnosed in 11% of children with JIA. It was more common in females than in males (13.1% vs 7.3% respectively). More than half of patients with uveitis (53.8%) had oligoarticular JIA, whereas 34.2% of patients had polyarticular RF-seronegative JIA. The majority of children (85.5%) received basic therapy, primarily with methotrexate (97% of them). Biologicals were administered to 64.1% of patients; of them, 68% received adalimumab. Sixty-one percent of children had bilateral eye lesions. In 41.5% of patients, the disease started with joint syndrome, while 46.3% of patients had both joint syndrome and eye lesions at onset and 12.2% of children initially had eye lesions. Remission of uveitis was registered in 75.6% of patients. Conclusion. Our results are consistent with both Russian and foreign data. Early diagnosis of uveitis and its timely treatment will decrease the incidence of complications in patients with JIA (including complete vision loss) and reduce the burden of disability for patients, their families, and the state. Key words: biological therapy, rheumatoid uveitis, rheumatic diseases in children, juvenile arthritis

Malignant Syphilis in a Young Patient With Juvenile Idiopathic Arthritis Under Biological Therapy

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Cecília Anatriello dos Santos ◽  
Luana Coelho Benevides ◽  
Renata Nahas Cardili ◽  
Gecilmara Cristina Salviato Pileggi ◽  
Virginia Paes Leme Ferriani ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Young Patient ◽  
Biological Therapy

THU0326 Drug survival and reasons for discontinuation of the first course of biological therapy in 301 juvenile idiopathic arthritis patients

2013 ◽  
Vol 71 (Suppl 3) ◽  
pp. 266.1-266
Author(s):  
M. Romano ◽  
I. Pontikaki ◽  
M. Gattinara ◽  
I. Ardoino ◽  
C. Donati ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
Biological Therapy ◽  
Drug Survival

scholarly journals HEMATOLOGICAL PARAMETERS AND CLINICAL OUTCOME IN INTENSIVE CARE UNIT OF A DEDICATED COVID HOSPITAL: A SPECIAL CONSIDERATION TO HEMOGLOBIN CONCENTRATION.

2021 ◽  
pp. 22-24
Author(s):  
Chetan S. Bhangale ◽  
Teli Shaikh Emaran Shaikh Ismail ◽  
Harshal M. Mahajan
Keyword(s):  
Intensive Care Unit ◽  
Intensive Care ◽  
Clinical Outcome ◽  
Hematological Parameters ◽  
Drug Prescription ◽  
Hemoglobin Concentration ◽  
Severe Form ◽  
Government Medical College ◽  
Medical College ◽  
Laboratory Investigations

Introduction:The world is currently facing the threat of the COVID-19 pandemic.It is well established that hemoglobin deficient state is associated with severe form of Covid19 disease. the present study was done assess the changes in hematological parameters with special reference to hemoglobin and clinical outcome in intensive care unit of a Dedicated COVID Hospital, Government Medical College,Jalgaon.Materials and Methods: The present study was of retrospective, analytical type conducted at Government Medical College, Jalgaon which was a Dedicated COVID hospital. We collected the data of demographics, co-morbidities, laboratory investigations, drug prescription and clinical outcome from the record section of medicine department after taking required permission.Results: Out of 111 patients with confirmed Covid19 infection, majority belonged to age group of 51-60 years (24.3%). Mean hemoglobin was not statistically different in survivor versus non-survivor analysis. Conclusion: Although the hematological parameters and inflammatory markers were significantly deranged in deceased patients as compared to cured patients, mean hemoglobin was not significantly different.Thus,as per the findings of present study mean hemoglobin cannot be considered as marker of prognosis in patients with moderate to severe Covid19 disease.

scholarly journals Successful treatment with belimumab of severe systemic lupus erythematosus not responding to standard therapy: a case report

2016 ◽  
Vol 10 (1) ◽  
pp. 3-6
Author(s):  
Ottavia Magnani ◽  
Elena Penza ◽  
Giuseppe Murdaca ◽  
Francesco Puppo
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Monoclonal Antibody ◽  
Lupus Erythematosus ◽  
Biological Therapy ◽  
Cervical Lymphadenopathy ◽  
Severe Form ◽  
High Dose ◽  
Systemic Lupus ◽  
Severe Systemic Lupus Erythematosus ◽  
Dsdna Antibodies

 Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by complex pathophysiology and heterogeneous clinical picture. Belimumab is the first biological therapy licensed for SLE. We report the case of a 24 years old woman affected by a severe form of systemic lupus erythematosus with arthritis, muscle weakness, cervical lymphadenopathy, cutaneous involvement, fever, leukopenia, low complement levels and positivity for anti-dsDNA antibodies. Treatment with high dose steroids, hydroxychloroquine, and mycophenolate mofetil did not induce remission and several disease flares were observed. Therapy with anti-BLys monoclonal antibody belimumab leads to a fast clinical and laboratory response and to stable remission lasting for 30 months allowing steroid tapering to very low maintenance dose. 

scholarly journals Immunology markers that can be predictive for the diagnosis of juvenile idiopathic arthritis

2020 ◽  
Vol 44 (1) ◽  
pp. 23-26
Author(s):  
Lucia M. Sur ◽  
Ciprian Silaghi ◽  
Marius C. Colceriu ◽  
Daniel G. Sur ◽  
Cornel Aldea ◽  
...  
Keyword(s):  
Juvenile Idiopathic Arthritis ◽  
High Performance ◽  
Antinuclear Antibodies ◽  
Pediatric Patients ◽  
Onset Age ◽  
Systemic Form ◽  
International League ◽  
Important Marker

Abstract Background This study aimed to investigate the implications of antinuclear antibodies (ANAs) in juvenile idiopathic arthritis (JIA), the association with uveitis and the favorable evolution of the disease. Methods We followed 45 pediatric patients suffering from JIA, according to the International League of Associations for Rheumatology (ILAR), for a period of 2 years. ANAs were followed through immunofluorescence methods using a high-performance immunofluorescence automatic Helios device. Results A total of 15 of the ANA-positive patients presented an oligoarticular form of the disease, eight of them presented a polyarticular form of the disease and two of them presented a systemic form. The most severe forms have associated iridocyclitis. ANA-positive patients presented an earlier onset of disease in comparison with ANA-negative ones. ANA-positive patients from different ILAR categories had similar characteristics of the disease such as onset age (earlier), higher prevalence in females and the presence of asymmetric arthritis or iridocyclitis. Conclusions ANA may be an important marker for JIA and association with iridocyclitis. Following ANA titer in evolution might be a criterion for assessing the evolution of the disease. The association between positive ANA, oligoarticular JIA, iridocyclitis and a 2- to 4-year-old onset is common.

Sign in / Sign up

Export Citation Format

Share Document